1. Home
  2. MUX vs OMER Comparison

MUX vs OMER Comparison

Compare MUX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MUX
  • OMER
  • Stock Information
  • Founded
  • MUX 1979
  • OMER 1994
  • Country
  • MUX Canada
  • OMER United States
  • Employees
  • MUX N/A
  • OMER N/A
  • Industry
  • MUX Precious Metals
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • MUX Basic Materials
  • OMER Health Care
  • Exchange
  • MUX Nasdaq
  • OMER Nasdaq
  • Market Cap
  • MUX 579.8M
  • OMER 513.8M
  • IPO Year
  • MUX N/A
  • OMER 2009
  • Fundamental
  • Price
  • MUX $18.61
  • OMER $7.68
  • Analyst Decision
  • MUX Strong Buy
  • OMER Strong Buy
  • Analyst Count
  • MUX 4
  • OMER 6
  • Target Price
  • MUX $19.63
  • OMER $27.50
  • AVG Volume (30 Days)
  • MUX 2.1M
  • OMER 8.3M
  • Earning Date
  • MUX 11-07-2025
  • OMER 11-07-2025
  • Dividend Yield
  • MUX N/A
  • OMER N/A
  • EPS Growth
  • MUX N/A
  • OMER N/A
  • EPS
  • MUX N/A
  • OMER N/A
  • Revenue
  • MUX $168,169,000.00
  • OMER N/A
  • Revenue This Year
  • MUX $5.13
  • OMER N/A
  • Revenue Next Year
  • MUX $19.34
  • OMER N/A
  • P/E Ratio
  • MUX N/A
  • OMER N/A
  • Revenue Growth
  • MUX N/A
  • OMER N/A
  • 52 Week Low
  • MUX $6.38
  • OMER $2.95
  • 52 Week High
  • MUX $24.88
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • MUX 51.29
  • OMER 61.26
  • Support Level
  • MUX $18.28
  • OMER $7.44
  • Resistance Level
  • MUX $20.66
  • OMER $8.05
  • Average True Range (ATR)
  • MUX 1.29
  • OMER 0.75
  • MACD
  • MUX -0.47
  • OMER 0.03
  • Stochastic Oscillator
  • MUX 5.00
  • OMER 45.06

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: